|
Nemours Community Clinical Oncology Program
|
3U10CA176879-01S1
|
$89,460
|
$4,473
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Development of Transporter Targeted Platinum Drugs for Pediatric Tumor
|
1R43CA183186-01
|
$190,000
|
$62,700
|
MAMELOK, RICHARD
|
APRICITY THERAPEUTICS, INC.
|
|
Bay Area Tumor Institute CCOP
|
3U10CA045461-24S1
|
$81,028
|
$2,431
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Improving T-cell therapies for neuroblastoma
|
5R01CA142636-05
|
$287,576
|
$287,576
|
DOTTI, GIANPIETRO
|
BAYLOR COLLEGE OF MEDICINE
|
|
Enhancing T Cell Therapy of Cancer
|
5P01CA094237-12
|
$1,874,319
|
$468,580
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Localization and Function of NKT Cells in Neuroblastoma
|
5R01CA116548-09
|
$227,424
|
$227,424
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S1
|
$75,000
|
$4,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S3
|
$48,834
|
$2,930
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S4
|
$149,801
|
$8,988
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-08
|
$2,746,741
|
$164,804
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
1R01CA174808-01A1
|
$326,348
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
""Oncorequisite"" Genes in MYC-mediated Transformation
|
5R00CA134743-05
|
$234,037
|
$46,807
|
FENG, HUI
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Engineering a supramolecular platinum nanoparticle for pediatric cancer
|
1R21CA186009-01
|
$215,682
|
$107,841
|
SENGUPTA, SHILADITYA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
1U10CA180884-01
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
1U10CA180886-01
|
$26,616,497
|
$2,129,320
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S1
|
$79,593
|
$6,367
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S2
|
$208,457
|
$16,677
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S3
|
$229,232
|
$18,339
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S4
|
$1,163,256
|
$93,060
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S5
|
$1,543,656
|
$123,492
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S6
|
$265,465
|
$21,237
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-01S7
|
$3,000,000
|
$240,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Copy number variations (CNVs) in neuroblastoma
|
5R00CA151869-05
|
$229,071
|
$229,071
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
5R01CA124709-07
|
$562,701
|
$562,701
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
2R01CA140198-06
|
$404,266
|
$404,266
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma
|
1R01CA182633-01
|
$704,800
|
$704,800
|
ASGHARZADEH, SHAHAB
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-07
|
$232,069
|
$232,069
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Center for Environment-Mediated Drug Resistance in Pediatric Cancer
|
5U54CA163117-04
|
$473,452
|
$345,620
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Biology and Therapy of High Risk Neuroblastoma
|
5P01CA081403-15
|
$1,925,523
|
$1,925,523
|
SEEGER, ROBERT
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
3U10CA045418-27S1
|
$237,321
|
$7,120
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
5U01CA168426-03
|
$1,165,605
|
$1,165,605
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
National Center: Multiscale Analysis of Genomic and Cellular Networks (MAGNet)
|
5U54CA121852-10
|
$3,589,179
|
$287,134
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
2P30CA013696-40
|
$3,596,904
|
$143,876
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-40S1
|
$125,000
|
$5,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-40S2
|
$50,000
|
$2,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-40S3
|
$320,000
|
$12,800
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-40S4
|
$75,000
|
$3,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Columbia University Medical Center Minority-Based Community Clinical Oncology Pro
|
3U10CA167791-02S1
|
$73,416
|
$2,202
|
KELLY, KARA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
3R01CA148688-04S1
|
$106,528
|
$106,528
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-04
|
$352,231
|
$352,231
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Uncovering the anti-apoptotic mechanism of mutated ALK in neuroblastoma
|
1F32CA183566-01A1
|
$51,530
|
$51,530
|
MOORE, NATHAN
|
DANA-FARBER CANCER INST
|
|
Cancer Specific Sensitivity to Suppression of Spliceosome Components
|
1F32CA180653-01A1
|
$53,282
|
$26,641
|
PAOLELLA, BRENTON
|
DANA-FARBER CANCER INST
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-06S1
|
$74,858
|
$749
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-06
|
$1,560,000
|
$15,600
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
5R01CA123490-07
|
$243,655
|
$60,914
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Berberine downregulates MDM2 by interaction with DAXX in cancer cells
|
5R01CA143107-05
|
$65,349
|
$32,675
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Duluth Community Clinical Oncology Program
|
3U10CA035269-30S1
|
$111,679
|
$3,350
|
NIKCEVICH, DANIEL
|
ESSENTIA INSTITUTE OF RURAL HEALTH
|
|
EORTC HEADQUARTERS
|
5U10CA011488-44
|
$155,961
|
$3,119
|
LACOMBE, DENIS
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Community Clinical Oncology Program: FL Pediatric CCOP
|
3U10CA035157-30S1
|
$46,850
|
$2,343
|
TALBERT, JAMES
|
FLORIDA ASSN OF PEDIATRIC TUMOR PROG
|
|
Cancer Center Support Grant (Comprehensive)
|
3P30CA015704-39S5
|
$10,116,159
|
$101,162
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
Total relevant funding to Neuroblastoma for this search: $23,581,708
|